Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
March 22, 2024 08:30 ET
|
Precision Neuroscience
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
February 27, 2024 08:00 ET
|
Healis Therapeutics
CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a...
Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego
February 12, 2024 08:00 ET
|
Healis Therapeutics
Healis' clinical program developing BoNT/A neuromodulator proteins has the potential to transform care for over 280 million patients with depression.
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
February 07, 2024 08:00 ET
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
February 05, 2024 07:00 ET
|
NodThera
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
January 30, 2024 09:18 ET
|
Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions
PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation
January 03, 2024 09:04 ET
|
Brain & Behavior Research Foundation
New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at...
Nexstim receives Nexstim NBS System 5 order from Europe for Neurosurgery and Neuroscience Use
December 22, 2023 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 22 December 2023 at 9 AM (EET) Nexstim receives Nexstim NBS System 5 order from Europe for Neurosurgery and Neuroscience Use Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company")...